Download PDF
Semin Liver Dis 2012; 32(02): 114-119
DOI: 10.1055/s-0032-1316466
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hepatitis B Virus and HIV Infection

Luz Martín-Carbonero
1   Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
,
Eva Poveda
1   Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2012 (online)

    Permissions and Reprints

Abstract

Approximately 5 to 10% of human immunodeficiency virus- (HIV-) infected persons worldwide have chronic hepatitis B virus (HBV). The management of these patients merits special attention. They experience a faster progression to cirrhosis and more frequent liver-related death than HBV-monoinfected individuals. For this reason, therapy for both HIV and HBV is a priority in most cases. Some antivirals (i.e., tenofovir, lamivudine, emtricitabine) are active against both viruses and should be part of the antiretroviral treatment choice. However, drugs such as entecavir, telbivudine, or adefovir are active against HBV and may display some residual activity against HIV, occasionally leading to the selection of resistance mutations in the HIV polymerase, as is clearly shown with entecavir. Thus, they should be used only in the context of potent antiretroviral treatment. In this review, the authors will provide updated information on the natural history of HIV/HBV coinfected patients, when and which drugs should be used in treatment, and the concern about selection of drug resistance and vaccine escape mutants.

Keywords

HIV - chronic hepatitis B virus - drug resistance - lamivudine - tenofovir
 

  • References

  • 1 Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14 (1) 1-21 , vii
    CrossrefPubMedGoogle Scholar
  • 2 Konopnicki D, Mocroft A, de Wit S , et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 2117-2125
    CrossrefPubMedGoogle Scholar
  • 3 Chun HM, Fieberg AM, Hullsiek KH , et al; Infectious Disease Clinical Research Program HIV Working Group. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010; 50 (3) 426-436
    CrossrefPubMedGoogle Scholar
  • 4 Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577
    CrossrefPubMedGoogle Scholar
  • 5 Soriano V, Mocroft A, Peters L , et al; EuroSIDA. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65 (3) 548-555
    CrossrefPubMedGoogle Scholar
  • 6 McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 (5, Suppl) S45-S55
    CrossrefPubMedGoogle Scholar
  • 7 Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3) 678-686
    CrossrefPubMedGoogle Scholar
  • 8 Chen CJ, Yang HI, Su J , et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1) 65-73
    CrossrefPubMedGoogle Scholar
  • 9 Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006; 44 (1, Suppl) S65-S70
    PubMedGoogle Scholar
  • 10 Walter SR, Thein HH, Amin J , et al. Trends in mortality after diagnosis of hepatitis B or C infection: 1992-2006. J Hepatol 2011; 54 (5) 879-886
    PubMedGoogle Scholar
  • 11 Martín-Carbonero L, Teixeira T, Poveda E , et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25 (1) 73-79
    CrossrefPubMedGoogle Scholar
  • 12 Clifford GM, Rickenbach M, Polesel J , et al; Swiss HIV Cohort. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22 (16) 2135-2141
    CrossrefPubMedGoogle Scholar
  • 13 Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49 (5, Suppl) S138-S145
    CrossrefPubMedGoogle Scholar
  • 14 Weber R, Sabin C, Friis-Moller N , et al. Liver-related deaths in persons with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-1641
    CrossrefPubMedGoogle Scholar
  • 15 Nikolopoulos GK, Paraskevis D, Hatzitheodorou E , et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48 (12) 1763-1771
    CrossrefPubMedGoogle Scholar
  • 16 Thio CL, Seaberg EC, Skolasky Jr R , et al; Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360 (9349) 1921-1926
    CrossrefPubMedGoogle Scholar
  • 17 Idoko J, Meloni S, Muazu M , et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49: 1268-1273
    CrossrefPubMedGoogle Scholar
  • 18 Dore GJ, Soriano V, Rockstroh J , et al; SMART INSIGHT study group. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24 (6) 857-865
    CrossrefPubMedGoogle Scholar
  • 19 Hoffmann CJ, Seaberg EC, Young S , et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009; 23 (14) 1881-1889
    CrossrefPubMedGoogle Scholar
  • 20 Sulkowski M, Thomas D, Chaisson R , et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80
    CrossrefPubMedGoogle Scholar
  • 21 Aceti A, Pasquazzi C, Zechini B, De Bac C ; LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29 (1) 41-48
    PubMedGoogle Scholar
  • 22 Soriano V, Puoti M, Garcia-Gascó P , et al. Antiretroviral drugs and liver injury. AIDS 2008; 22 (1) 1-13
    CrossrefPubMedGoogle Scholar
  • 23 Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study. AIDS 2004; 18 (15) 2039-2045
    CrossrefPubMedGoogle Scholar
  • 24 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services; . Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescenGL.pdf . Accessed October 21, 2011
    Google Scholar
  • 25 European AIDS Clinical Society. European AIDS Clinical Society Guidelines. Version 6.0, October, 2011. Available at: http://www.europeanaidsclinicalsociety.org . Accessed December 2, 2011
    PubMedGoogle Scholar
  • 26 Soriano V, Puoti M, Peters M , et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22 (12) 1399-1410
    CrossrefPubMedGoogle Scholar
  • 27 Vries-Sluijs T, Reijnders J, Hansen B , et al. Long-term therapy with tenofovir is effective for patients coinfected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139: 1934-1941
    CrossrefPubMedGoogle Scholar
  • 28 Landrum ML, Huppler Hullsiek K, Ganesan A , et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27 (34) 4731-4738
    CrossrefPubMedGoogle Scholar
  • 29 Cruciani M, Mengoli C, Serpelloni G , et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27 (1) 17-22
    CrossrefPubMedGoogle Scholar
  • 30 Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118 (Suppl 10A) 75S-83S
    CrossrefPubMedGoogle Scholar
  • 31 Keeffe EB, Dieterich DT, Han SH , et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6 (12) 1315-1341 , quiz 1286
    CrossrefPubMedGoogle Scholar
  • 32 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2) 227-242
    CrossrefPubMedGoogle Scholar
  • 33 Soriano V, Sheldon J, Ramos B, Núñez M. Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. AIDS 2006; 20 (3) 451-453
    CrossrefPubMedGoogle Scholar
  • 34 Li WC, Wang MR, Kong LB, Ren WG, Zhang YG, Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis 2011; 11: 165
    CrossrefPubMedGoogle Scholar
  • 35 Di Martino V, Thevenot T, Colin JF , et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123 (6) 1812-1822
    CrossrefPubMedGoogle Scholar
  • 36 Chang TT, Gish RG, De Man R , et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354 (10) 1001-1010
    CrossrefPubMedGoogle Scholar
  • 37 Lai CL, Shouval D, Lok AS , et al; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354 (10) 1011-1020
    CrossrefPubMedGoogle Scholar
  • 38 Tenney DJ. Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir Ther 2010; 15 (3 Pt B) 529-535
    CrossrefPubMedGoogle Scholar
  • 39 McMahon MA, Jilek BL, Brennan TP , et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med 2007; 356 (25) 2614-2621
    CrossrefPubMedGoogle Scholar
  • 40 Soriano V, Vispo E, Barreiro P. New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. AIDS 2011; 25 (7) 1013-1014
    CrossrefPubMedGoogle Scholar
  • 41 Ratcliffe L, Beadsworth M, Pennell A, Fillips M, Vilar FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truv. ada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 2011; 25 (8) 1051-1056
    CrossrefPubMedGoogle Scholar
  • 42 Ruiz-Sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opin Biol Ther 2007; 7 (5) 751-761
    CrossrefPubMedGoogle Scholar
  • 43 Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV-1. AIDS 2009; 23 (4) 546-547
    CrossrefPubMedGoogle Scholar
  • 44 Lin K, Karwowska S, Lam E, Limoli K, Evans TG, Avila C. Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro. Antimicrob Agents Chemother 2010; 54 (6) 2670-2673
    CrossrefPubMedGoogle Scholar
  • 45 Sheldon J, Rodès B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat 2006; 13 (7) 427-434
    CrossrefPubMedGoogle Scholar
  • 46 Kwon H, Lok M. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 275-284
    PubMedGoogle Scholar
  • 47 Karatayli E, Karayalçin S, Karaaslan H , et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007; 12 (5) 761-768
    PubMedGoogle Scholar
  • 48 Benhamou Y, Bochet M, Thibault V , et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30: 1302-1306
    CrossrefPubMedGoogle Scholar
  • 49 Hoffmann CJ, Charalambous S, Martin DJ , et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47 (11) 1479-1485
    CrossrefPubMedGoogle Scholar
  • 50 Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis 2008; 47 (11) 1486-1489
    CrossrefPubMedGoogle Scholar
  • 51 Matthews GV, Bartholomeusz A, Locarnini S , et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20 (6) 863-870
    CrossrefPubMedGoogle Scholar
  • 52 Gouskos T, Wightman F, Chang J , et al. Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient. AIDS 2004; 18 (12) 1734-1737
    CrossrefPubMedGoogle Scholar
  • 53 Hsu CW, Yeh CT, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology 2007; 132 (2) 543-550
    CrossrefPubMedGoogle Scholar
  • 54 Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61 (4) 766-768
    CrossrefPubMedGoogle Scholar
  • 55 Martín-Carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. J Antimicrob Chemother 2010; 65 (3) 379-382
    CrossrefPubMedGoogle Scholar
  • 56 Sheldon J, Camino N, Rodés B , et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10 (6) 727-734
    PubMedGoogle Scholar
  • 57 Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16 (1) 131-133
    CrossrefPubMedGoogle Scholar
  • 58 Tuma P, Pineda JA, Labarga P , et al; CoRIS Study Group. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther 2011; 16 (4) 585-589
    CrossrefPubMedGoogle Scholar
  • 59 Xu Z, Liu Y, Xu T , et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 2010; 48 (4) 270-274
    CrossrefPubMedGoogle Scholar
  • 60 Fung S, Mazulli T, El-Kashab M , et al. Lamivudine-resistant mutation among treatment-naïve hepatitis B patients is common and may be associated with treatment failure. Abstract presented at: Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, CA; Abstract 888
    PubMedGoogle Scholar